News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Visterra, Inc. To Present Data At ICAAC On VIS513, Its Humanized Monoclonal Antibody That Targets A Conserved Site On The Dengue Virus E Protein


9/3/2014 8:53:04 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Visterra, Inc., a biotechnology company that uses its proprietary technology platform to identify unique disease targets and design novel therapeutics, today announced that new preclinical data for VIS513 will be presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Washington, D.C.

“VIS513 was developed using Visterra’s innovative and proprietary technology and we are very encouraged by these new data which show the potential of VIS513 to broadly neutralize all four dengue virus serotypes,” said Brian J. G. Pereira, M.D., President and Chief Executive Officer of Visterra. “Currently there is no specific treatment for dengue and prevention depends solely on limiting or eradicating mosquitoes that transmit the virus. VIS513 has demonstrated a rapid reduction in viral titers after a single systemic administration, which supports its potential use as a treatment for dengue virus infection. Based on these data, we plan to advance its development and enter the clinic in 2015.”

Hey, check out all the research scientist jobs. Post your resume today!

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES